Skip to content

Canceled by the investigator. Clinical application of Human myeloid nuclear differentiation antigen (MNDA) in early diagnosis of urogenic sepsis

Clinical application of MNDA in early diagnosis of urogenic sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076532
Enrollment
Unknown
Registered
2023-10-11
Start date
2023-10-15
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urinary system /infection

Interventions

Gold Standard:The diagnosis of urosepsis typically requires the following two primary criteria: 1.Positive blood culture: This is determined through microbiological examination of a blood sample, wher
Index test:Among the patients who met the inclusion criteria, blood was extracted for analysis of Human myeloid nuclear differentiation antigen (MNDA) after obtaining the informed consent of the patie

Sponsors

The Second Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Men and women between the ages of 18 and 75; 2. Meet any point of a/b below a) Positive blood culture; b) Urine culture positive, blood leukocytes, procalcitonin and other infection indicators increased significantly, and accompanied by obvious symptoms such as fever and chills; 3. Have not participated in other related medical research within the past 6 months; 4. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Non-urogenic sepsis; 2. Pregnant patients under 18 years old; 3. Complicated with malignant tumor, tuberculosis, blood disease, diabetes and heart disease; 4. Complicated with other serious urological diseases; 5. Infection of other sites is present.

Design outcomes

Primary

MeasureTime frame
procalcitonin;Human myeloid nuclear differentiation antigen;c-reactive protein;Plasma leukocyte;blood culture;AUC;sensitiveness;specificity;Optimal cutoff value;

Countries

China

Contacts

Public ContactWenqi Wu

The Second Affiliated Hospital of Guangzhou Medical University

wwqwml@163.com+86 136 0908 9242

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026